Vetter announces plans to expand its capacity in the U.S. and Germany
![](/46/pdcnewsitem/12/46/20/Foto.jpg)
- Vetter Advisory
Board decides on strategic path forward for further independent and sustainable
growth
- Des Plaines, IL,
and Saarlouis, Germany expansions add to an ongoing 1.5 billion Euro investment
plan
- Vetter adds
capacity within its core business of the clinical and commercial injectable
filling of complex compounds
Ravensburg,
Germany & Skokie / Des Plaines, IL (June 6, 2024):
Vetter, a leading global contract development and manufacturing organization
(CDMO), announced its plans to move and expand its Development Services site
from Skokie, Illinois, to Des Plaines, further investing in its U.S. footprint.
Simultaneously, the company plans additional major investment in its commercial
business in the state of Saarland, located in the Southwest of Germany bordering
France and Luxembourg, to complement its growth and capacity expansions in
Ravensburg and Langenargen which are currently underway. This adds more
capacity for future customers around the globe as the injectable industry is
witnessing a rise in outsourcing development, manufacturing, assembly and
packaging needs to CDMOs.
“As
an independent and family-owned company, we prioritize thoughtful and strategic
planning to support our long-term business growth,” shared Senator h.c. Udo J.
Vetter, Chairman of the Advisory Board and member of the owner family. “With
these investments we reaffirm our commitment on both continents and enable that
Vetter Pharma will continue to be part of a growing market in the future.”
Building on Existing
Investments
A
few years ago, Vetter made a strategic investment by
acquiring the Des Plaines site, demonstrating progressive thinking in business
development. The recent decision by the Advisory Board will elevate Vetter
Development Services to a new level, driven by growing customer needs at the
current Skokie site, as well as at the company’s clinical manufacturing site in
Rankweil, Austria.
This
development plan involves a construction project at the Des Plaines site and
the relocation and expansion of Vetter Development Services U.S. from the
Illinois Science and Technology Park over the next years. New buildings for
clinical manufacturing and related services will be constructed. The move will
effectively double the capacity of Vetter Development Services in the U.S. and
provide ample space for future expansion opportunities.
Path-Forward for Commercial
Expansion Plans
Vetter
executives have been given the approval to exercise an additional commercial
production site in Saarlouis, Saarland. This decision aligns with the recently
approved ‘German Pharmaceutical Strategy‘, and the significant growth of
investments in research and production facilities in Germany by leading
pharmaceutical companies. Another factor for this decision is the extensive
experience of the CDMO with production building projects in Germany, which will
enhance the predictability of construction costs and planning time. In
addition, this experience supports immediate access to an existing network of
suppliers and the use of the company’s internal infrastructure.
The
Saarland government plans to develop a technology park on the site in Saarlouis.
Vetter has already started planning the phased development of a 125 acre site.
The planned investment amounts to a value of several hundred million Euro.
Pharmaceutical production at the site is expected to start by 2030 and Vetter
is planning to create up to 2,000 new local jobs in the years to come.
Managing
Director Thomas Otto stated: “After careful consideration, Germany, and
Saarland in particular, prove to be the location with the best-fitting
conditions for expanding our commercial operations. In addition to the existing
and growing competencies and capacities at and around our sites in Ravensburg,
we will be able to further expand our range of services. We are taking
responsibility for patients and customers worldwide who rely on our high level
of quality.”
Contributions to Increased Supply
with Life-Saving Medications
In
its ongoing commitment to serve customers and their patients worldwide, Vetter
is expanding its capacity for handling complex injectables. These expansions
are part of the CDMO's comprehensive, sustainable, and long-term plan to
position the company for future growth in serving drug product development,
aseptic injectable filling, device assembly and packaging.
“The
approval of the Advisory Board aligns with our commitment to meet the long-term
capacity needs of our clinical and commercial customers and their patients,”
added Managing Director Peter Soelkner. “We know that the multiannual-long
investments at our Ravensburg and Langenargen sites will contribute to this,
however the market and our customers are in need of even more capacity. We are
proud to announce further investments in Des Plaines, IL, USA, and Germany.”
![Vetter Pharma-Fertigung GmbH & Co. KG](https://www.cphi-online.com/c245215th_S-comp245215.jpg)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance